Title | The NF-κB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Nilsson-Payant BE, Uhl S, Grimont A, Doane AS, Cohen P, Patel RS, Higgins CA, Acklin JA, Bram Y, Chandar V, Blanco-Melo D, Panis M, Lim JK, Elemento O, Schwartz RE, Rosenberg BR, Chandwani R, tenOever BR |
Journal | J Virol |
Volume | 95 |
Issue | 23 |
Pagination | e0125721 |
Date Published | 2021 Nov 09 |
ISSN | 1098-5514 |
Keywords | A549 Cells, Animals, Chlorocebus aethiops, COVID-19, Cytokines, Epigenomics, Gene Expression Regulation, HEK293 Cells, HeLa Cells, Host Microbial Interactions, Humans, Interferon Type I, SARS-CoV-2, Signal Transduction, Single-Cell Analysis, Transcription Factor RelA, Transcription Factors, Transcriptome, Vero Cells, Virus Replication |
Abstract | SARS-CoV-2, the etiological agent of COVID-19, is characterized by a delay in type I interferon (IFN-I)-mediated antiviral defenses alongside robust cytokine production. Here, we investigate the underlying molecular basis for this imbalance and implicate virus-mediated activation of NF-κB in the absence of other canonical IFN-I-related transcription factors. Epigenetic and single-cell transcriptomic analyses show a selective NF-κB signature that was most prominent in infected cells. Disruption of NF-κB signaling through the silencing of the NF-κB transcription factor p65 or p50 resulted in loss of virus replication that was rescued upon reconstitution. These findings could be further corroborated with the use of NF-κB inhibitors, which reduced SARS-CoV-2 replication . These data suggest that the robust cytokine production in response to SARS-CoV-2, despite a diminished IFN-I response, is the product of a dependency on NF-κB for viral replication. The COVID-19 pandemic has caused significant mortality and morbidity around the world. Although effective vaccines have been developed, large parts of the world remain unvaccinated while new SARS-CoV-2 variants keep emerging. Furthermore, despite extensive efforts and large-scale drug screenings, no fully effective antiviral treatment options have been discovered yet. Therefore, it is of the utmost importance to gain a better understanding of essential factors driving SARS-CoV-2 replication to be able to develop novel approaches to target SARS-CoV-2 biology. |
DOI | 10.1128/JVI.01257-21 |
Alternate Journal | J Virol |
PubMed ID | 34523966 |
PubMed Central ID | PMC8577386 |
Grant List | T32 AI007647 / AI / NIAID NIH HHS / United States / / Bill and Melinda Gates Foundation (BMGF) / S10 OD026880 / OD / NIH HHS / United States AI151029-01A1 / / Foundation for the National Institutes of Health (FNIH) / R01 DK121072 / DK / NIDDK NIH HHS / United States R01 AI151029 / AI / NIAID NIH HHS / United States |